Elkholy Karim O, Hegazy Omar, Okunade Adeniyi, Aktas Suat, Ajibawo Temitope
Internal Medicine, Brookdale University Hospital Medical Center, New York, USA.
Internal Medicine, Mercy Hospital, Chicago, USA.
Cureus. 2021 Jan 27;13(1):e12940. doi: 10.7759/cureus.12940.
Regadenoson is a pharmacological stress agent that has been widely used since its approval by the Food and Drug Administration (FDA) in 2008. For many years, dipyridamole and adenosine, which are non-selective adenosine receptor agonists, were more popular. However, these agents are less preferred now due to their undesirable adverse effects as compared to regadenoson. In the ADVANCE (ADenoscan Versus regAdenosoN Comparative Evaluation) phase 3 clinical trial, regadenoson demonstrated non-inferiority to adenosine for detecting reversible myocardial ischemia. This review summarizes the clinical utilities of regadenoson as the most widely used pharmacological stress agent. Moreover, the use of regadenoson has been documented in specific patient populations. Although regadenoson has established safety and efficacy in most patients with chronic diseases, there are equivocal results in the literature for other chronic diseases. It is warranted to highlight that the use of regadenoson has not been studied in patients of low socioeconomic class; it is a condition that carries a significant burden on the cardiovascular system.
雷加昔布是一种药物应激剂，自2008年获得美国食品药品监督管理局（FDA）批准以来已被广泛使用。多年来，非选择性腺苷受体激动剂双嘧达莫和腺苷更受欢迎。然而，与雷加昔布相比，这些药物由于不良副作用而较少被选用。在ADVANCE（腺苷扫描与雷加昔布对比评估）3期临床试验中，雷加昔布在检测可逆性心肌缺血方面显示出不劣于腺苷。本综述总结了雷加昔布作为最广泛使用的药物应激剂的临床应用。此外，雷加昔布在特定患者群体中的使用已有文献记载。虽然雷加昔布在大多数慢性病患者中已确立了安全性和有效性，但在其他慢性病的文献中结果并不明确。值得强调的是，尚未对社会经济地位较低的患者使用雷加昔布进行研究；这是一种给心血管系统带来重大负担的情况。
